Figure 1From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot studyTrial profile. Six-month data were obtained on all but four patients. At 12-month visit, pulmonary function tests were available in 22 patients. PNX, pneumothorax.Back to article page